← Eichor
Study identifier: NCT06947499 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

Condition: Diphtheria · Tetanus · Pertussis  ·  Sponsor: LG Chem

PhasePhase 2/Phase 3
Planned participants1186
Who can joinAll sexes, 6 Weeks to 8 Weeks
Healthy volunteersYes

About this study

The purpose of this study is to evaluate immunogenicity, safety and lot-to-lot consistency of LBVD in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Study Lead  ·  +82-2-6987-4156  ·  lgclinical@lgchem.com

Always discuss trial participation with your own doctor first.

Locations (1)

Care CT GroupDasmariñas, Cavite, PhilippinesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06947499